ReviewMolecules and cells2015
Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives.
Review in Molecules and cells, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- HypoxamiRs: the hidden architects of tissue adaptation in hypoxia.Cell death & disease · 2025Review
- An Overview of In Vitro Models of Alcohol-Related Hepatocellular Carcinoma.Cancer medicine · 2025Review
- The dual role of autophagy in suppressing and promoting hepatocellular carcinoma.Frontiers in cell and developmental biology · 2024Review
- Tumor matrix stiffness provides fertile soil for cancer stem cells.Cancer cell international · 2023Review
- The regulatory effect of the YY1/miR‑HCC2/BAMBI axis on the stemness of liver cancer cells.International journal of oncology · 2023Article
- Roles of cancer stem cells in gastrointestinal cancers.World journal of stem cells · 2023Review
- Hepatitis B Virus Surface Antigen Promotes Stemness of Hepatocellular Carcinoma through Regulating MicroRNA-203a.Journal of clinical and translational hepatology · 2023Article
- Inhibitory effects of LOXL2 knockdown on cellular functions of liver cancer stem cells.Translational cancer research · 2022Article
- Article
- The role of mesenchymal stem cells in the occurrence, development, and therapy of hepatocellular carcinoma.Cancer medicine · 2022Review
- Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.Theranostics · 2021Review
- The Cancer Stem Cell in Hepatocellular Carcinoma.Cancers · 2020Review
- HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines.Journal of Cancer · 2020Article
- MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1.International journal of biological sciences · 2019Article
- YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway.Cancer cell international · 2019Article
- Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.Therapeutic advances in gastroenterology · 2019Review
- MicroRNA-31 suppresses the self-renewal capability of α2δ1Oncotarget · 2017Article
- USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.Molecular oncology · 2017Article
- STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer.Medicine · 2017Observational
- Molecular Pathogenesis of Hepatocellular Carcinoma.Liver cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), a highly malignant disease and the third leading cause of all cancer mortalities worldwide, often responses poorly to current treatments and results in dismal outcomes due to frequent chemoresistance and tumor relapse. The heterogeneity of HCC is an important attribute of the disease. It is the outcome of many factors, including the cross-talk between tumor cells within the tumor microenvironment and the acquisition and accumulation of genetic and epigenetic alterations in tumor cells. In addition, there is accumulating evidence in recent years to show that the malignancy of HCC can be attributed partly to the presence of cancer stem cell (CSC). CSCs are capable to self-renew, differentiate and initiate tumor formation. The regulation of the stem cell-like properties by several important signaling pathways have been found to endow the tumor cells with an increased level of tumorigenicity, chemoresistance, and metastatic ability. In this review, we will discuss the recent findings on hepatic CSCs, with special emphasis on their putative origins, relationship with hepatitis viruses, regulatory signaling networks, tumor microenvironment, and how these factors control the stemness of hepatic CSCs. We will also discuss some novel therapeutic strategies targeted at hepatic CSCs for combating HCC and perspectives of future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.